Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Bacterial Infections: Page 3
T2 Biosystems wins Medicare payment approval
By
LabPulse.com staff writers
As of October 1, 2019, U.S. hospitals treating Medicare inpatients with sepsis will now be eligible for a maximum NTAP amount of $97.50 -- 65% of the list price for one test -- for the T2Bacteria panel in addition to the appropriate sepsis diagnosis-related group (MS-DRG) reimbursement that hospitals receive under the Medicare hospital inpatient prospective payment system (IPPS), according to T2. The T2Bacteria panel is designed to detect sepsis-causing bacterial pathogens in the bloodstream in three to five hours without a blood culture.
August 6, 2019
GlaxoSmithKline recruits SpeeDx for antibiotics trials
By
LabPulse.com staff writers
SpeeDx markets in vitro testing products internationally that are aimed at minimizing the spread of treatment-resistant infections. Such products include ResistancePlus GC for Neisseria gonorrhoeae bacteria, which recently received the breakthrough device designation from the U.S. Food and Drug Administration (FDA), and ResistancePlus MG for detecting the emerging sexually transmitted infection Mycoplasma genitalium (Mgen). In a statement, the company said that it will use its existing molecular diagnostic tests as well as custom products to assist GlaxoSmithKline in ongoing trials and new product development.
June 23, 2019
Labs gear up to diagnose novel fungal infection
By
Bruce Carlson
In the past few years, more than 600 cases of an emerging fungal infection called Candida auris have been identified in 12 U.S. states, according to the CDC.
April 14, 2019
Previous Page
Page 3 of 3